Alvotech (ALVO) News Today → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free ALVO Stock Alerts $13.88 +0.11 (+0.80%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 7:02 AM | marketbeat.com2 Generic Drug Makers With Growing RunwaysBrand-name drug costs continue to climb, but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. Generics are loved by health insurers, Medicare, and patients as they contain the same compounds and active ingredients for a cheaper price.May 31 at 7:00 AM | marketbeat.com2 Generic Drug Makers With Growing Runways (ALVO)Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out.May 29 at 8:05 AM | globenewswire.comAlvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024May 29 at 8:04 AM | globenewswire.comAlvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024May 27, 2024 | americanbankingnews.comAlvotech (NYSE:ALVO) Price Target Raised to $22.00May 25, 2024 | sg.finance.yahoo.comTEVA Jan 2025 21.000 putMay 25, 2024 | finance.yahoo.comBrokers Are Upgrading Their Views On Alvotech (NASDAQ:ALVO) With These New ForecastsMay 24, 2024 | americanbankingnews.comCritical Survey: Gritstone bio (NASDAQ:GRTS) and Alvotech (NYSE:ALVO)May 23, 2024 | finance.yahoo.comAlvotech First Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)May 22, 2024 | finance.yahoo.comAlvotech and Dr Reddy’s partner to commercialise AVT03May 21, 2024 | investorplace.comALVO Stock Earnings: Alvotech Misses EPS for Q1 2024May 21, 2024 | globenewswire.comAlvotech Reports Financial Results for First Quarter of 2024 and Provides a Business UpdateMay 21, 2024 | globenewswire.comAlvotech Reports Financial Results for First Quarter of 2024 and Provides a Business UpdateMay 21, 2024 | globenewswire.comAlvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UKMay 21, 2024 | globenewswire.comAlvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UKMay 20, 2024 | globenewswire.comTeva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.May 20, 2024 | globenewswire.comTeva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.May 20, 2024 | businesswire.comTeva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.May 15, 2024 | globenewswire.comAlvotech S.A. Annual General Meeting to be held June 7, 2024May 13, 2024 | finance.yahoo.comAlvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)May 13, 2024 | globenewswire.comAlvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)May 13, 2024 | globenewswire.comAlvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)May 2, 2024 | globenewswire.comAlvotech Announces Participation at BofA Securities Healthcare Conference 2024May 2, 2024 | globenewswire.comAlvotech Announces Participation at BofA Securities Healthcare Conference 2024April 30, 2024 | finance.yahoo.comAlvotech (ALVO)April 30, 2024 | businesswire.comU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)April 30, 2024 | globenewswire.comU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)April 30, 2024 | globenewswire.comU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)April 24, 2024 | globenewswire.comAlvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)April 24, 2024 | globenewswire.comAlvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)April 21, 2024 | uk.investing.comAlvotech expands US reach with biosimilar to HumiraApril 19, 2024 | globenewswire.comAlvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)April 19, 2024 | globenewswire.comAlvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)April 17, 2024 | markets.businessinsider.comAlvotech And Teva : FDA Approves Selarsdi Injection For Psoriasis And Psoriatic ArthritisApril 16, 2024 | marketwatch.comAlvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis TreatmentApril 16, 2024 | msn.comFDA approves Alvotech biosimilar of J&J top-selling drug StelaraApril 16, 2024 | finance.yahoo.comAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)April 3, 2024 | globenewswire.comAlvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024April 3, 2024 | globenewswire.comAlvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024March 23, 2024 | seekingalpha.comAlvotech (ALVO) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | globenewswire.comAlvotech Announces Increase in Number of Own SharesMarch 22, 2024 | globenewswire.comAlvotech Announces Increase in Number of Own SharesMarch 22, 2024 | finance.yahoo.comAnalysts Expect Breakeven For Alvotech (NASDAQ:ALVO) Before LongMarch 22, 2024 | uk.finance.yahoo.comQ4 2023 Alvotech SA Earnings CallMarch 20, 2024 | investorplace.comALVO Stock Earnings: Alvotech Reported Results for Q4 2023March 20, 2024 | globenewswire.comAlvotech Reports Financial Results for Full Year 2023 and Provides a Business UpdateMarch 20, 2024 | globenewswire.comAlvotech Reports Financial Results for Full Year 2023 and Provides a Business UpdateMarch 16, 2024 | finance.yahoo.comTEVA Mar 2024 10.000 callMarch 6, 2024 | finance.yahoo.comTEVA Mar 2024 15.500 putMarch 5, 2024 | globenewswire.comAlvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Email Address Who are Nvidia’s New Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself. I call these Nvidia’s “Silent Partners.” ALVO Media Mentions By Week ALVO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALVO News Sentiment▼0.260.81▲Average Medical News Sentiment ALVO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALVO Articles This Week▼73▲ALVO Articles Average Week Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ACONW News Today DRTSW News Today AONC News Today ARTLW News Today BIAFW News Today BCTXW News Today BFRGW News Today CCLDP News Today CCLDO News Today CNTG News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALVO) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyOn June 10, Nvidia makes its next big moveWeiss RatingsMAJOR BUY SIGNAL: Move Fast, Washington/Pelosi/Mill…AltimetryUnlock Explosive Gains with This Defense StockBehind the MarketsElon’s Revenge on BidenTradeSmithClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alvotech Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
